Dr. Leandro Bueno Bergantin
Department of Pharmacology, Federal University of São Paulo, Brazil
Dr. Bergantin received his academic education at EPM-UNIFESP (Brazil) and UAM (Spain): biomedicine (2008), MSc (2010) and PhD (2014). His research work solved the enigma of the paradoxical effects produced by L-type Ca2+ channel blockers (ScienceDirect TOP 25 Hottest Articles - Biochemistry, Genetics and Molecular Biology - Cell Calcium). Since 1975, several clinical and experimental studies have reported that acute and chronic administration of L-type Ca2+ channel blockers (CCB), such as nifedipine, produces reduction in arterial pressure associated with a paradoxical increase of sympathetic activity. In 2013, Dr. Bergantin and collaborators discovered that this paradoxical increase in sympathetic activity produced by Ltype CCB is due to interaction of the Ca2+/cAMP signaling pathways. Then, the pharmacological manipulation of this interaction could be a new therapeutic strategy for increasing neurotransmission in psychiatric disorders, and producing neuroprotection in the neurodegenerative diseases (Bergantin and Caricati-Neto, 2016 Eur J Pharmacol; CaricatiNeto et al., 2015 Pharm Res Perspect). In addition, the pharmacological handling of the Ca2+/cAMP signaling interaction could be a more efficient therapeutic approach to inhibit cancer tumor progression (Errante PR et al., 2017 Adv Cancer Prev). Dr. Bergantin has published several articles in international journals (>40), book chapters and an international book. He is member of several editorial boards of international journals (>60, including editorin-chief of 3 international journals). Dr. Bergantin has been frequently invited (every week) to be honorable guest (speaker) in international conferences, and to participating in media interviews.
Biochemistry, Genetics and Molecular Biology